http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 09:03:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jun+02/26588752.html si-local-file:///var/storage/secattach/20260602/26588752.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jun+02/26588752.html Tue, 02 Jun 2026 09:03:00 -0400 O.02608059 ONCY http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jun+02/26588752.html si-local-file:///var/storage/secattach/20260602/26588752.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ONCOLYTICS+BIOTECH+INC++++For%3A+Jun+02/26588752.html Tue, 02 Jun 2026 09:03:00 -0400 O.02608059 ONCY http://www.streetinsider.com/Board+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to chief operating officer.</p> <p>Glover brings public company leadership and transaction experience to the clinical-stage biotechnology company. He previously served as chairman of Ambrx Biopharma during its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion.</p> <p>McAdory, who joined Oncolytics earlier this year from CG Oncology where he served as vice president of clinical operations, will oversee the company's clinical operations, development activities, and preclinical research. He will also play a role in strategic partnerships and http://www.streetinsider.com/Board+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html Tue, 02 Jun 2026 09:00:51 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Board+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to chief operating officer.</p> <p>Glover brings public company leadership and transaction experience to the clinical-stage biotechnology company. He previously served as chairman of Ambrx Biopharma during its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion.</p> <p>McAdory, who joined Oncolytics earlier this year from CG Oncology where he served as vice president of clinical operations, will oversee the company's clinical operations, development activities, and preclinical research. He will also play a role in strategic partnerships and http://www.streetinsider.com/Board+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html Tue, 02 Jun 2026 09:00:51 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Board+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to chief operating officer.</p> <p>Glover brings public company leadership and transaction experience to the clinical-stage biotechnology company. He previously served as chairman of Ambrx Biopharma during its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion.</p> <p>McAdory, who joined Oncolytics earlier this year from CG Oncology where he served as vice president of clinical operations, will oversee the company's clinical operations, development activities, and preclinical research. He will also play a role in strategic partnerships and http://www.streetinsider.com/Board+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html Tue, 02 Jun 2026 09:00:51 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Board+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to chief operating officer.</p> <p>Glover brings public company leadership and transaction experience to the clinical-stage biotechnology company. He previously served as chairman of Ambrx Biopharma during its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion.</p> <p>McAdory, who joined Oncolytics earlier this year from CG Oncology where he served as vice president of clinical operations, will oversee the company's clinical operations, development activities, and preclinical research. He will also play a role in strategic partnerships and http://www.streetinsider.com/Board+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html Tue, 02 Jun 2026 09:00:51 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Board+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to chief operating officer.</p> <p>Glover brings public company leadership and transaction experience to the clinical-stage biotechnology company. He previously served as chairman of Ambrx Biopharma during its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion.</p> <p>McAdory, who joined Oncolytics earlier this year from CG Oncology where he served as vice president of clinical operations, will oversee the company's clinical operations, development activities, and preclinical research. He will also play a role in strategic partnerships and http://www.streetinsider.com/Board+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html Tue, 02 Jun 2026 09:00:51 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Board+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to chief operating officer.</p> <p>Glover brings public company leadership and transaction experience to the clinical-stage biotechnology company. He previously served as chairman of Ambrx Biopharma during its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion.</p> <p>McAdory, who joined Oncolytics earlier this year from CG Oncology where he served as vice president of clinical operations, will oversee the company's clinical operations, development activities, and preclinical research. He will also play a role in strategic partnerships and http://www.streetinsider.com/Board+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html Tue, 02 Jun 2026 09:00:51 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Management+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to chief operating officer.</p> <p>Glover brings public company leadership and transaction experience to the clinical-stage biotechnology company. He previously served as chairman of Ambrx Biopharma during its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion.</p> <p>McAdory, who joined Oncolytics earlier this year from CG Oncology where he served as vice president of clinical operations, will oversee the company's clinical operations, development activities, and preclinical research. He will also play a role in strategic partnerships and http://www.streetinsider.com/Management+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html Tue, 02 Jun 2026 09:00:51 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Management+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to chief operating officer.</p> <p>Glover brings public company leadership and transaction experience to the clinical-stage biotechnology company. He previously served as chairman of Ambrx Biopharma during its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion.</p> <p>McAdory, who joined Oncolytics earlier this year from CG Oncology where he served as vice president of clinical operations, will oversee the company's clinical operations, development activities, and preclinical research. He will also play a role in strategic partnerships and http://www.streetinsider.com/Management+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html Tue, 02 Jun 2026 09:00:51 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Management+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to chief operating officer.</p> <p>Glover brings public company leadership and transaction experience to the clinical-stage biotechnology company. He previously served as chairman of Ambrx Biopharma during its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion.</p> <p>McAdory, who joined Oncolytics earlier this year from CG Oncology where he served as vice president of clinical operations, will oversee the company's clinical operations, development activities, and preclinical research. He will also play a role in strategic partnerships and http://www.streetinsider.com/Management+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html Tue, 02 Jun 2026 09:00:51 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Management+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to chief operating officer.</p> <p>Glover brings public company leadership and transaction experience to the clinical-stage biotechnology company. He previously served as chairman of Ambrx Biopharma during its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion.</p> <p>McAdory, who joined Oncolytics earlier this year from CG Oncology where he served as vice president of clinical operations, will oversee the company's clinical operations, development activities, and preclinical research. He will also play a role in strategic partnerships and http://www.streetinsider.com/Management+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html Tue, 02 Jun 2026 09:00:51 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Management+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to chief operating officer.</p> <p>Glover brings public company leadership and transaction experience to the clinical-stage biotechnology company. He previously served as chairman of Ambrx Biopharma during its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion.</p> <p>McAdory, who joined Oncolytics earlier this year from CG Oncology where he served as vice president of clinical operations, will oversee the company's clinical operations, development activities, and preclinical research. He will also play a role in strategic partnerships and http://www.streetinsider.com/Management+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html Tue, 02 Jun 2026 09:00:51 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Management+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html <p>Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to chief operating officer.</p> <p>Glover brings public company leadership and transaction experience to the clinical-stage biotechnology company. He previously served as chairman of Ambrx Biopharma during its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion.</p> <p>McAdory, who joined Oncolytics earlier this year from CG Oncology where he served as vice president of clinical operations, will oversee the company's clinical operations, development activities, and preclinical research. He will also play a role in strategic partnerships and http://www.streetinsider.com/Management+Changes/Oncolytics+Biotech+adds+Steve+Glover+to+board%2C+promotes+John+McAdory+to+COO/26588615.html Tue, 02 Jun 2026 09:00:51 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html <p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer (“COO”).</p> <p align="justify">Mr. Glover brings significant public company leadership and transaction experience to Oncolytics, including serving as Chairman of Ambrx http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html Tue, 02 Jun 2026 09:00:00 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html <p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer (“COO”).</p> <p align="justify">Mr. Glover brings significant public company leadership and transaction experience to Oncolytics, including serving as Chairman of Ambrx http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html Tue, 02 Jun 2026 09:00:00 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html <p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer (“COO”).</p> <p align="justify">Mr. Glover brings significant public company leadership and transaction experience to Oncolytics, including serving as Chairman of Ambrx http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html Tue, 02 Jun 2026 09:00:00 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html <p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer (“COO”).</p> <p align="justify">Mr. Glover brings significant public company leadership and transaction experience to Oncolytics, including serving as Chairman of Ambrx http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html Tue, 02 Jun 2026 09:00:00 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html <p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer (“COO”).</p> <p align="justify">Mr. Glover brings significant public company leadership and transaction experience to Oncolytics, including serving as Chairman of Ambrx http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html Tue, 02 Jun 2026 09:00:00 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html <p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer (“COO”).</p> <p align="justify">Mr. Glover brings significant public company leadership and transaction experience to Oncolytics, including serving as Chairman of Ambrx http://www.streetinsider.com/Press+Releases/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html Tue, 02 Jun 2026 09:00:00 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html <p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer (“COO”).</p> <p align="justify">Mr. Glover brings significant public company leadership and transaction experience to Oncolytics, including serving as Chairman of Ambrx http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html Tue, 02 Jun 2026 09:00:00 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html <p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer (“COO”).</p> <p align="justify">Mr. Glover brings significant public company leadership and transaction experience to Oncolytics, including serving as Chairman of Ambrx http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html Tue, 02 Jun 2026 09:00:00 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html <p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer (“COO”).</p> <p align="justify">Mr. Glover brings significant public company leadership and transaction experience to Oncolytics, including serving as Chairman of Ambrx http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html Tue, 02 Jun 2026 09:00:00 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html <p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer (“COO”).</p> <p align="justify">Mr. Glover brings significant public company leadership and transaction experience to Oncolytics, including serving as Chairman of Ambrx http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html Tue, 02 Jun 2026 09:00:00 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html <p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer (“COO”).</p> <p align="justify">Mr. Glover brings significant public company leadership and transaction experience to Oncolytics, including serving as Chairman of Ambrx http://www.streetinsider.com/Globe+Newswire/Oncolytics+Biotech%C2%AE+Announces+Appointment+of+Steve+Glover+to+Board+of+Directors+and+Promotion+of+John+McAdory+to+Chief+Operating+Officer/26588591.html Tue, 02 Jun 2026 09:00:00 -0400 A.34221934 A.50114190 O.02316246 O.02608059 O.50710440 ONCY